In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas

Executive Summary

The biopharma industry enjoyed regulatory success in 2012 that was recognized by investors. The stench from the carcasses of industry’s genericized blockbusters has begun to fade, but R&D productivity for the most part remains poor, expensive late-stage failures abound, and industry is still searching for sustainable business models.


Related Content

FDA’s Very Big Year: Drug Approvals Approach Record Levels
Too Big To Succeed: Where Are Large Pharmas Heading?
The Orphan Drug Boom: Gold Rush Or Flash In The Pan?
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy
Will The New Math Of Oncology Drug Review Times Carry Over Into PDUFA V?
Solution Development: A Model For Structuring Biotechs And Developing Better Drugs
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
Merck, GSK, J&J Broaden Strategic LP Relationships, External Discovery Initiatives
Biopharma In 2011: A Year Of Transition
IND Over POC: The New Sweet Spot For Biopharma Dealmaking


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts